We recently encountered a situation where an individual used artificial intelligence (AI) to ask questions about Medicare enrollment and compare available health plan options. Unfortunately, the information provided by the AI was inaccurate, creating confusion about enrollment requirements and plan choices. When the individual contacted our agency for assistance, we were able to review the information, identify the errors, and provide accurate guidance based on their specific circumstances and available coverage options.
This experience highlights both the potential and the limitations of AI when it comes to important healthcare decisions. While AI can be a helpful starting point for gathering information, Medicare rules, enrollment deadlines, provider networks, prescription coverage, and plan benefits can be complex and vary by individual and location. AI should be a tool for information, not a replacement for knowledgeable, licensed insurance professionals. Working with an experienced health insurance broker helps ensure that information is verified, questions are answered accurately, and coverage decisions are made with a clear understanding of the options available.
Coming Government Regulations:
The U.S. Food and Drug Administration (FDA) is developing new policies for regulating generative artificial intelligence (AI) in healthcare, potentially evaluating these systems more like human physicians than traditional medical software. Rick Abramson, MD, director of the FDA’s Digital Health Center of Excellence, confirmed that the agency intends to develop formal guidance. The FDA recently received more than 300 public comments on how generative AI products should be evaluated for safety and effectiveness before reaching the market. Although no timeline has been announced for proposed regulations, the agency plans to carefully review the feedback before moving forward.
The American Medical Association (AMA) supports incorporating physician expertise into AI evaluation standards and emphasizes that manufacturers must remain accountable for their products’ performance. The AMA also stresses that patient safety and effectiveness should take priority over speeding up regulatory approval. As generative AI becomes more capable of supporting clinical decisions and patient care, the FDA’s forthcoming policies could significantly influence how these technologies are tested, approved, and used across healthcare, including radiology.
